RE-DUAL PCI – In Review

PART 1: RE-DUAL PCI – Switching of NOACs after PCI in patients with atrial fibrillation

Educational objectives

  • Understand the latest data in relation to the NOACs and its implication on selected subgroups of populations.
  • Interpret the new data on the treatment of patients with atrial fibrillation and when to apply dual vs triple therapy treatment.
  • Understand the implementation of the emerging data and which patient groups should be treated differently.
Jur ten Berg
Prof Jur ten Berg is Head of the St Antonius Center for Platelet Function Studies at the St Antonius Hospital, The Netherlands, where he also serves as Director of the Cardiology Training Programme. He has published over 400 peer-reviewed articles.

 


Programme Outline
  • PART 1: RE-DUAL PCI – Switching of NOACs after PCI in patients with atrial fibrillationJur ten Berg
  • PART 2: RE-DUAL PCI – Diabetes sub-group analysisChristopher P Cannon
This video series was funded by an unrestricted educational service from Boehringer Ingelheim.

PART 2: RE-DUAL PCI – Diabetes sub-group analysis